Tekla Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tekla Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-57,700	Closed	-$4.49M	–	147
2016 Q2	$4.49M	Buy	+57,700	New	+$4.91M	0.18%	93
2015 Q4	–	Sell	-35,500	Closed	-$3.74M	–	138
2015 Q3	$3.74M	Buy	+35,500	New	+$4.74M	0.13%	116

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tekla Capital Management's BMRN Position: Q2 2023 in Review

Tekla Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 30% in Q2 2023, selling an estimated $8.4M and leaving 210,789 shares worth $18.3M. The position accounts for 0.72% of the portfolio, ranked #40.

Tekla Capital Management first reported a position in BMRN in Q2 2013 and has held it in 41 quarters since. The position peaked at $73.2M in Q2 2015. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Tekla Capital Management held 210,789 shares of BioMarin Pharmaceuticals worth $18.3M as of Q2 2023.
Tekla Capital Management sold 89,300 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $8.4M.
BioMarin Pharmaceuticals made up 0.72% of Tekla Capital Management's portfolio in Q2 2023, its #40 holding.
Tekla Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
Tekla Capital Management's BioMarin Pharmaceuticals position peaked at $73.2M in Q2 2015.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.